Therapeutic approaches in patients with inflammatory myopathies

Seminars in Neurology

Volumn 23, Issue 2, 2003, Pages 199-206

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Dermatomyositis; Inclusion body myositis; Polymyositis

Indexed keywords

AMYLOID; AZATHIOPRINE; CHEMOKINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACNE; ALOPECIA; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DERMATOMYOSITIS; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; ECCHYMOSIS; EDEMA; FATTY LIVER; GASTROINTESTINAL DISEASE; GLAUCOMA; GROWTH RETARDATION; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; INFERTILITY; INFLAMMATION; LEUKOPENIA; LIVER TOXICITY; LUNG FIBROSIS; MENSTRUATION DISORDER; META ANALYSIS; MUSCLE DISEASE; NAUSEA; NEPHROTOXICITY; OBESITY; OSTEOPOROSIS; PLASMAPHERESIS; PNEUMONIA; POLYMERIZATION; POLYMYOSITIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMATITIS; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TUBERCULOSIS; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFLAMMATORY AGENTS; DERMATOMYOSITIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; STEROIDS;

EID: 0041842435     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41136     Document Type: Review

References (28)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991;325:1487-1498
2. Dalakas MC, Karpati G. The inflammatory myopathies. In: Karpati G, Hilton-Jones D, Griggs RC, eds. Disorders of Voluntary Muscle. 7th ed. Cambridge: Cambridge University Press; 2001:636-659
3. Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis. Arch Neurol 1991;48:1229-1234
4. Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology 1992;42:460-461
5. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. In press
6. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995;37:74-86
7. Dalakas MC. The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 2001;1:300-306
8. Dalakas MC. Progress in inflammatory myopathies: good but not good enough [editorial]. J Neurol Neurosurg Psychiatry 2001;70:569-573
9. Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfeld R. T cell receptor in polymyositis: clonal expression of autoaggressive CD8+T cells. J Exp Med 1995;181:1863-1868
10. Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: studies in repeated muscle biopsies. Brain 2000;123:2030-2039
11. Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 1998;161:5943-5951
12. Murata K, Dalakas MC. Expression of the co-stimulatory molecule BB-1, the ligand CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999;155:453-460
13. Dalakas MC. Current treatment of inflammatory myopathies. Curr Opin Rheumatol 1994;6:595-601
14. Dalakas MC. The treatment of polymyositis, dermatomyositis and Inclusion body myositis. In: Johnson RT, Griffin JW, eds. Current Therapy in Neurology. St. Louis: Mosby Year Book; 1996:407-412
15. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-122
16. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukopheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380-1384
17. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999;22:1479-1497
18. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000
19. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-control study. Neurology 1997;48:712-716
20. Dalakas MC, Koffman BM, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327
21. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-28
22. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58:326
23. Peterson EJ, Koretzky GA. Signal transduction in T lymphocytes. Clin Exp Rheumatol 1999;17:107-114
24. Gold R, Dalakas MC,Toyka KV. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurology 2003;2:22-32
25. Hohlfeld R, Dalakas MC. Basic principles of immunotherapy for neurologic diseases. Semin Neurol 2003;23:121-132
26. Dalakas MC. How to diagnose and treat the inflammatory myopathies. Sem Neurol 1994;14:137-145
27. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347
28. Mastaglia FL. Treatment of autoimmune inflammatory myopathies. Curr Opin Neurol 2000;13:507-509